BeUlight has successfully completed U.S. Food and Drug Administration (FDA) Registration in accordance with the relevant requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
This achievement establishes an important compliance foundation for Wanshen (Beijing) Plasma Technology Co., Ltd. to support future market activities in the United States and further strengthens the company's global regulatory framework.
Prior to this milestone, the BeUlight Plasma-Activated Teeth Whitening System obtained CE Certification in October 2025. Following its CE certification, the successful completion of FDA Registration further strengthens BeUlight's regulatory readiness across two major international markets, Europe and North America, supporting the company's continued global expansion.
The achievement of both CE Certification and FDA Registration reflects more than a single regulatory milestone. It demonstrates BeUlight's ongoing commitment to research and development, quality management, manufacturing standards, and product safety systems.
For innovative oral aesthetic technologies, regulatory compliance serves not only as a pathway to international markets but also as a foundation for sustainable long-term growth.This achievement demonstrates that BeUlight's plasma teeth whitening solution is supported by quality and management systems aligned with international market expectations, creating a strong platform for future growth.
Based on EU CE and FDA certifications, Wanshen (Beijing) Plasma Technology Co., Ltd. will further promote the global application and market implementation of plasma teeth whitening technology. We will also cooperate with professional institutions worldwide to drive technological innovation and standard development in dental aesthetics and oral health.
